MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 14 special meeting

Lite Strategy, Inc.

Board reiterates recommendation to approve merger with Infinity Pharmaceuticals (INFI) at July 14 special meeting.
Combined pipeline includes three clinical-stage programs: eganelisib, voruciclib (with Venclexta), and ME-344 (with Avastin).
Key data expected from voruciclib and ME-344 by year-end 2023; eganelisib is a Phase 2 first-in-class PI3K-gamma inhibitor.
Combined company will have experienced drug development team and is positioned to advance diversified oncology pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.